Literature DB >> 20661912

The role of kinesin family proteins in tumorigenesis and progression: potential biomarkers and molecular targets for cancer therapy.

Yue Yu1, Yu-Mei Feng.   

Abstract

The kinesin superfamily contains a conserved class of microtubule-dependent molecular motor proteins that possess an adenosine triphosphatase activity and motion characteristics. The active movement of kinesins supports several cellular functions, including mitosis, meiosis, and the transport of macromolecules. Mitosis is a process of eukaryotic cell division that involves the division of nuclei, cytoplasm, organelles, and the cell membrane into 2 daughter cells with roughly equivalent portions of these cellular components. Any errors in this process could result in cell death, abnormality (such as gene deletion, chromosome translocation, or duplication), and cancer. Because mitosis is complex and highly regulated, alteration of kinesin expression or function could lead to carcinogenesis. Moreover, because human cancer is a gene-related disease involving abnormal cell growth, targeting kinesins may create a novel strategy for the control of human cancer. Indeed, several such drugs are being tested successfully in the clinic. In this review, the authors discuss in detail the structure and function of kinesins, the correlation of kinesin expression with tumorigenesis and progression, and the development of biomarkers and cancer-targeted therapy involving the kinesin family proteins.
Copyright © 2010 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20661912     DOI: 10.1002/cncr.25461

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  46 in total

Review 1.  Targeting mitotic pathways for endocrine-related cancer therapeutics.

Authors:  Shivangi Agarwal; Dileep Varma
Journal:  Endocr Relat Cancer       Date:  2017-06-14       Impact factor: 5.678

2.  A TOP2A-derived cancer panel drives cancer progression in papillary renal cell carcinoma.

Authors:  Mushi Ye; Zhuobin He; Wei Dai; Zhuo Li; Xiaojun Chen; Jianjun Liu
Journal:  Oncol Lett       Date:  2018-07-19       Impact factor: 2.967

3.  Role of a Kinesin Motor in Cancer Cell Mechanics.

Authors:  Kalpana Mandal; Katarzyna Pogoda; Satabdi Nandi; Samuel Mathieu; Amal Kasri; Eric Klein; François Radvanyi; Bruno Goud; Paul A Janmey; Jean-Baptiste Manneville
Journal:  Nano Lett       Date:  2019-10-07       Impact factor: 11.189

4.  Expression signatures of early-stage and advanced medaka melanomas.

Authors:  Barbara Klotz; Susanne Kneitz; Martina Regensburger; Lena Hahn; Michael Dannemann; Janet Kelso; Birgit Nickel; Yuan Lu; William Boswell; John Postlethwait; Wesley Warren; Manfred Kunz; Ronald B Walter; Manfred Schartl
Journal:  Comp Biochem Physiol C Toxicol Pharmacol       Date:  2017-11-21       Impact factor: 3.228

5.  MiR-19a/miR-96-mediated low expression of KIF26A suppresses metastasis by regulating FAK pathway in gastric cancer.

Authors:  Ran-Ran Ma; Hui Zhang; Hong-Fang Chen; Guo-Hao Zhang; Ya-Ru Tian; Peng Gao
Journal:  Oncogene       Date:  2021-03-05       Impact factor: 9.867

6.  Functional analysis of KIF20A, a potential immunotherapeutic target for glioma.

Authors:  Katsuya Saito; Shigeki Ohta; Yutaka Kawakami; Kazunari Yoshida; Masahiro Toda
Journal:  J Neurooncol       Date:  2017-01-09       Impact factor: 4.130

Review 7.  New therapeutic targets in soft tissue sarcoma.

Authors:  Elizabeth G Demicco; Robert G Maki; Dina C Lev; Alexander J Lazar
Journal:  Adv Anat Pathol       Date:  2012-05       Impact factor: 3.875

8.  Phenotypic Screening of Chemical Libraries Enriched by Molecular Docking to Multiple Targets Selected from Glioblastoma Genomic Data.

Authors:  David Xu; Donghui Zhou; Khuchtumur Bum-Erdene; Barbara J Bailey; Kamakshi Sishtla; Sheng Liu; Jun Wan; Uma K Aryal; Jonathan A Lee; Clark D Wells; Melissa L Fishel; Timothy W Corson; Karen E Pollok; Samy O Meroueh
Journal:  ACS Chem Biol       Date:  2020-05-21       Impact factor: 5.100

9.  KIF22 promotes progress of esophageal squamous cell carcinoma cells and is negatively regulated by miR-122.

Authors:  Jian Wang; Peng-Yi Yu; Jing-Ping Yu; Ju-Dong Luo; Zhi-Qiang Sun; Fei Sun; Ze Kong; Jian-Lin Wang
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

10.  Sox17 inhibits hepatocellular carcinoma progression by downregulation of KIF14 expression.

Authors:  Tao Yang; Xiao-Na Li; Li Li; Qi-Mei Wu; Peng-Zhi Gao; Hong-Lei Wang; Wei Zhao
Journal:  Tumour Biol       Date:  2014-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.